Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Montelukast in COVID-19 Pneumonia
NCT04718285Phase 2Unknown
- Sponsor
- Bahçeşehir University
- Start
- May 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of montelukast in COVID-19 pneumonia (3 arms), sponsored by Bahçeşehir University. Primary endpoint: Hospitalized patient rates at 15 days. Status: unknown.
02
Drugs
montelukast
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04718285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04718285.